abstract |
The present invention relates to a method for predicting a subject's risk of rapidly progressing to chronic heart failure and/or hospitalization and/or death due to chronic heart failure. The present invention is based on at least one biomarker selected from the group consisting of BNP-type peptide, IGFBP7 (IGF-binding protein 7), cardiac troponin, soluble ST2 (sST2), FGF-23 (fibroblast growth factor 23) and growth differentiation factor 15 (GDF‑15). The method may further comprise assessing the presence or absence of (i) abnormal intramural fractional shortening or (ii) left ventricular hypertrophy. The present invention further contemplates apparatus suitable for carrying out the present invention. |